An adjuvanted influenza vaccine for adults 65 years of age and older2

NACI recommends adjuvanted inactivated influenza vaccine as an option for adults 65 years of age and older1

See the complete NACI Supplemental guidance on influenza vaccination in adults 65 years of age and older for more information.

INFLUENZA. CONSIDER THE BURDEN TO YOUR PATIENTS OVER 65

CUMULATIVE NUMBERS OF ADULT HOSPITALIZATIONS
(≥65 YEARS OF AGE) WITH INFLUENZA BY AGE GROUP

Reported by the Canadian Immunization Research Network (CIRN) – Serious Outcomes Surveillance (SOS) network, Canada, Weeks 2019-45 to 2020-193

In the 2019-2020 flu season:

  • Among the 629 cases with influenza A, the largest proportion of hospitalizations was in adults 65 years of age and older (66%).
  • Among the 170 cases with influenza B, 52% were in adults 65 years of age and older.3

SELECT LABORATORY-CONFIRMED INFLUENZA DETECTIONS IN ADULTS AGED 65 YEARS AND OLDER3

In the 2019-2020 season, the cases reported for adults 65 years of age and older were:3

Influenza A:

  • - 46% (largest proportion) of 2,057 cases of A/H3N2
  • - 28% of 3,740 cases of A/H1N1

A(H1N1) was the predominant subtype.

Influenza B:

  • - 7.7% of 18,194 cases

FLUAD® is not indicated to reduce complications or mortality associated with influenza.

WHAT IS FLUAD®?

A VACCINE TO HELP PREVENT
SEASONAL INFLUENZA

FLUAD® is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and B contained in the vaccine in adults 65 years of age and older.

WHAT IMMUNOGENICITY DATA ARE AVAILABLE FOR FLUAD® IN ADULTS AGED 65 YEARS AND OLDER?

FLUAD® STUDIES EVALUATING SEROCONVERSION AND GMT IN PATIENTS 65 YEARS OF AGE AND OLDER*

The immunogenicity of FLUAD® was evaluated compared with conventional non-adjuvanted influenza vaccines in 5 clinical trials (V7P5, V7P8, V7P17, V7P24, V7P34).2

In all 5 pivotal clinical trials:2†

  • Consistent numerically higher HI antibody titers (i.e., Day 28 GMT FLUAD®/comparator ratio >1) were observed for FLUAD®.
  • Greater percentages of subjects achieving seroconversion or significant increase in HI titres (i.e., vaccine group difference for the seroconversion rate of FLUAD®/comparator >0) for homologous strains were observed for FLUAD®.
  • Not all differences were statistically significant.

Demonstrated immune responses‡ at Day 28 following vaccination with FLUAD® vs. a conventional non-adjuvanted influenza vaccine (AGRIFLU®) in adult patients 65 years of age and older (Study V7P5)2§

Seroconversion rate differences

GMT ratios

Adapted from the FLUAD® Product Monograph2

CI=confidence interval; GMT=geometric mean titre; N=number of subjects in per-protocol population.
* Clinical significance unknown.
† Five randomized, comparator controlled, observer blind clinical studies evaluated the immunogenicity of FLUAD® compared with conventional non-adjuvanted influenza vaccines. In these studies, 212, 204, 154, 150 and 448 subjects 65 years and older were enrolled to receive FLUAD®.
‡ HI antibody titers to each virus strain in the vaccine.
§ Randomized, comparator-controlled, observer-blind clinical study in which the immunogenicity of FLUAD® (N=94) was compared with AGRIFLU® (N=97).
¶ Not statistically significant.

HOW IS FLUAD® ADMINISTERED?

FLUAD® REQUIRES ONE DOSE IN PATIENTS AGED ≥65 YEARS

FLUAD® is administered as one 0.5 mL intramuscular dose, preferably in the region of the deltoid muscle of the upper arm.2

The vaccine should not be injected in the gluteal region or areas where there may be a major nerve trunk.

FLUAD® should, under no circumstances, be administered by any other route than intramuscularly. Please see the FLUAD® Product Monograph for complete administration information.

References:

  • Government of Canada. National Advisory Committee on Immunization (NACI). Supplemental guidance on influenza vaccination in adults 65 years of age and older (advance copy).
  • Seqirus Canada Inc., FLUAD® Product Monograph.
  • Government of Canada. Flu Watch Report: July 19 to August 22, 2020 (Weeks 30-34). Available at: https://www. canada.ca/en/public-health/services/publications/diseases-conditions/fluwatch/2019-2020/weeks-30-34-july-19- august-22-2020.html.

ORDER FLUAD®

To order FLUAD®, please contact us at: customerservice.ca@seqirus.com

MORE INFORMATION

SUPPORT MATERIAL AND LINKS

Download a range of flu awareness and FLUAD® materials to support your clinic in the fight against flu.

READ MORE
CAN-FLUD-24-0001E
FLUAD®, MF59® and AGRIFLU® are registered trademarks of Seqirus UK Limited or its affiliates.
© CSL Seqirus Canada Inc. 2024
This website has been developed by CSL Seqirus Canada Inc. This website is for use by Canadian healthcare professionals and associated healthcare employees only.